Immunocombination therapy for high-risk neuroblastoma

Area of Science:

• Oncology
• Immunology
• Pediatric Cancer Research

Background:

• Neuroblastoma (NBL) is a highly aggressive pediatric cancer originating from the sympathetic nervous system.
• Advanced-stage NBL presents a significant challenge, with a 5-year mortality rate around 50%, necessitating novel therapeutic strategies.
• Current treatments require enhancement, driving the need for innovative approaches like immunotherapy.

Purpose of the Study:

• To review established neuroblastoma treatments.
• To highlight the potential and prerequisites of cell-based immunotherapies for NBL.
• To discuss the combined application of immunotherapy with novel tumor-targeted therapies.

Main Methods:

• Review of existing literature on neuroblastoma treatments.
• Analysis of current and emerging immunotherapeutic approaches, including monoclonal antibodies and dendritic cell-based therapies.
• Exploration of the synergistic potential between immunotherapy and targeted tumor therapies.

Main Results:

• Immunotherapy, including monoclonal antibodies and dendritic cell therapies, shows promise but benefits only a subset of patients.
• Cell-based immunotherapy involves both innate and adaptive immune-effector cells, offering new avenues for treatment.
• Combination therapies integrating immunotherapy with novel tumor-targeted treatments present significant opportunities.

Conclusions:

• There is an urgent need for improved treatment modalities for neuroblastoma.
• Cell-based immunotherapy holds considerable promise for neuroblastoma treatment, requiring further investigation into its prerequisites and optimization.
• Combining immunotherapy with novel tumor-targeted therapies may offer enhanced efficacy for neuroblastoma and other cancers.